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EXPERT OPINION
Abstract: Atypical antipsychotic medications have assumed growing importance for the
treatment of bipolar disorder, an illness that affects approximately 1.2%–3.7% of the general
population in a given year. Current practice guidelines for the treatment of bipolar mania
support the use of atypical antipsychotic medications as monotherapy or as a component of
polytherapy, and in clinical settings the use of atypical antipsychotics to treat bipolar disorder
is widespread. Risperidone is an atypical antipsychotic, sometimes referred to as a second-
generation antipsychotic. The receptor-binding profile of risperidone, which includes potent
antagonism of the serotonin 5-HT2A, dopamine D2, and alpha-adrenergic receptors, is believed
to be related to positive effects on mood. The FDA-approved bipolar indications for risperidone
include: 1) monotherapy for short-term treatment of acute manic or mixed episodes associated
with bipolar I disorder and 2) combination therapy with lithium or valproate for the short-
term treatment of acute manic or mixed episodes associated with bipolar I disorder. This
review of risperidone for bipolar mania will address the chemistry, pharmacodynamics,
pharmacokinetics, and metabolism of risperidone, use with concomitant medications, clinical
trials in bipolar mania, as well as safety and tolerability issues. Finally, dosing and
administration are addressed as well as use for bipolar mania in geriatric, child, or adolescent
patients.
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Introduction
Atypical antipsychotic medications have assumed growing importance for the
treatment of bipolar disorder, an illness that affects approximately 1.2%–3.7% of the
general population in a given year (Regier et al 1993; Hirschfeld et al 2003). For
bipolar mania in particular, the atypical antipsychotics have demonstrated efficacy
and generally good tolerability. Current practice guidelines for the treatment of bipolar
mania support the use of atypical antipsychotic medications as monotherapy or as a
component of polytherapy (APA 2002). In clinical settings the use of atypical
antipsychotics to treat bipolar disorder is widespread. A recent report based upon a
large US registry of over 65 000 individuals with bipolar disorder noted that in 2001,
more than 40% of individuals with bipolar disorder were prescribed antipsychotic
medications, and that 85% of these were on atypical antipsychotics (Sajatovic et al
2004).
Most published bipolar disorder treatment trials focus on the use of atypical
antipsychotics as anti-manic agents, although literature on the use of atypical
antipsychotics in other phases of bipolar disorder illness is accumulating (Calabrese
et al 2005). In 2000, olanzapine was the first atypical antipsychotic to receive a Food
and Drug Administration (FDA) bipolar mania indication. Subsequent FDA approvals
for bipolar mania indications were received for risperidone in 2003 and 3 additional
compounds in 2004, quetiapine, ziprasidone, and aripiprazole.
Risperidone is an atypical antipsychotic, sometimes referred to as a second-
generation antipsychotic. While it was the second atypical antipsychotic to come to
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the US market overall, risperidone was the first atypical
antipsychotic recommended as a first-line treatment for the
management of schizophrenia. The receptor-binding profile
of risperidone, which includes potent antagonism of the
serotonin 5-HT2A, dopamine D2, and alpha-adrenergic
receptors, is believed to be related to positive effects on mood
(Leyson et al 1994; Pania and Gessab 2002; Kalkman and
Loetscher 2003; Hirschfeld et al 2004). The FDA-approved
bipolar indications for risperidone include: 1) monotherapy
for short-term treatment of acute manic or mixed episodes
associated with bipolar I disorder and 2) combination
therapy with lithium or valproate for the short-term treatment
of acute manic or mixed episodes associated with bipolar I
disorder.
This review of risperidone for bipolar mania will address
the chemistry, pharmacodynamics, pharmacokinetics, and
metabolism of risperidone, use with concomitant
medications, clinical trials in bipolar mania, as well as safety
and tolerability issues. Finally, dosing and administration
are addressed as well as use for bipolar mania in geriatric,
child, or adolescent patients, which are unapproved off-label
uses at this time.
Chemistry of risperidone
Risperidone is a benzisoxazole antipsychotic. The chemical
designation is 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-
piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-
pyrido[1,2-a]pyrimidin-4-one. Its molecular formula is
C23H27FN4O2 and its molecular weight is 410.49.
Pharmacodynamics,
pharmacokinetics, and metabolism
of risperidone
Risperidone is a selective monoaminergic antagonist with
high affinity (Ki 0.12–7.3 nM) for the 5-HT2, D2, alpha1,
and alpha2 adrenergic and H1 histaminergic receptors. It
has low to moderate affinity (Ki 253 nM) for the serotonin
(5-HT1c, 5-HT1d, and 5-HT1a) receptors, weak affinity (Ki
620–800 nM) for the dopamine D1 and the haloperidol-
sensitive sigma site, and no affinity for cholinergic
muscarinic or B1 and B2 adrenergic receptors.
Risperidone is well absorbed. Food does not affect the
rate and extent of absorption. The absolute oral bio-
availability of risperidone solution is 70%. Bioavailability
of the oral tablets as well as the orally disintegrating tablets
is 66%. Plasma concentrations of risperidone, 9-
hydroxyrisperidone (its major active metabolite), and the
combination of risperidone and 9-hydroxyrisperidone are
dose proportional over the dosage range of 1–16 mg/day.
Peak plasma concentrations occur at about 1 hour in
extensive metabolizers and 3 hours in poor metabolizers.
Risperidone is bound to albumin and alpha1-acid
glycoprotein. The plasma-protein binding of risperidone is
90% while the 9-hydroxyrisperidone metabolite is 77%
bound. Risperidone is extensively metabolized in the liver.
The main metabolic pathway is through hydroxylation of
risperidone to 9-hydroxyrisperidone via the enzyme
CYP2D6. The rate of metabolism through CYP2D6
is dependent on genetic polymorphism (Janssen
Pharmaceuticals 2003b). The main metabolite, 9-hydroxy-
risperidone, has similar pharmacological activity to
risperidone. Therefore, the clinical effects of the drug results
from the combined concentrations of risperidone plus
9-hydroxyrisperidone (active moiety). Risperidone and its
metabolites are eliminated via the urine and to a much
lesser extent via the feces. The half-lives of risperidone and
9-hydroxyrisperidone are 3 hours and 21 hours, respectively,
in extensive metabolizers, and 20 hours and 30 hours,
respectively, in patients who are poor metabolizers. The
overall mean elimination half-life of the active moiety is
approximately 20 hours.
Risperidone is available as a standard oral tablet, a fast-
dissolving tablet, and an oral solution, as well as a long-
acting injection. Alternatives to a standard oral formulation
may be of particular use in situations where patients may
have difficulty swallowing pills or where medication
adherence is a concern. The long-acting dosage formulation
uses the extended-release Medisorb (Medisorb Technologies
International LP, Cincinnati OH, USA) drug-delivery
system: small polymeric microspheres degrade slowly,
releasing the medication at a controlled rate. The long-acting
injection of risperidone exhibits different pharmacokinetics
from the standard oral formulation. After a single
intramuscular injection there is a small initial release of drug
(< 1% of the dose), followed by a lag time of 3 weeks and
subsequent release of risperidone. Therefore, oral
antipsychotic supplementation should be given for at least
3 weeks after the administration of the initial intramuscular
injection of long-acting risperidone to maintain therapeutic
levels until the main release of risperidone from the injection
site has begun (Janssen Pharmaceuticals 2003a).
The apparent half-life of risperidone plus 9-hydroxy-
risperidone following intramuscular administration is 3–6
days and is associated with a monoexponential decline in
plasma concentrations. This half-life is the result ofNeuropsychiatric Disease and Treatment 2006:2(2) 129
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microsphere erosion and subsequent absorption of
risperidone. The elimination phase is complete 7–8 weeks
after the last injection. Steady-state plasma concentrations
of the long-acting intramuscular dosage form are reached
after 4 injections and are maintained for 4–6 weeks after
the last injection. Similar to the oral dosage form of
risperidone, plasma concentrations of the intramuscular form
of risperidone, 9-hydroxyrisperidone, and risperidone plus
9-hydroxyrisperidone are linear over the dosing range of
25–50 mg. The combination of the release profile and the
dosage regimen (intramuscular injections every 2 weeks)
of long-acting risperidone results in sustained therapeutic
concentrations.
Patients with either renal or hepatic disease have not
been studied using long-acting risperidone. Based on the
studies with oral risperidone, it is recommended that these
patients be carefully titrated on oral risperidone before
starting on long-acting risperidone.
 Elderly patients, who
can tolerate 2 mg/day, can be started on 25 mg every 2 weeks
and maintained on the regular dosing schedule.
Use of risperidone with
concomitant medications
Risperidone, a CYP2D6 substrate, could be subject to 2
kinds of drug–drug interactions (Janssen Pharmaceuticals
2003b). First, inhibitors of CYP2D6 interfere with the
conversion of risperidone to 9-hydroxyrisperidone.
Examples of drugs that inhibit CYP2D6, and therefore
risperidone metabolism, include fluoxetine and paroxetine.
Combined use of risperidone and one of these SSRIs will
require the clinician to review risperidone dosing and the
patient’s clinical status. A dosage adjustment may be needed.
The second type of drug–drug interaction could result from
co-administration of risperidone with a known enzyme
inducer such as carbamazepine, phenytoin, rifampin, or
phenobarbital. This co-administration could result in a
decrease in the combined plasma concentrations of
risperidone and 9-hydroxyrisperidone. For example, plasma
concentrations of risperidone and 9-hydroxyrisperidone
may be decreased by 50% with concomitant use of
carbamazepine. If carbamazepine is initiated a dosage
increase may be needed. Conversely, if carbamazepine is
discontinued, a decrease in dosage may be needed. Of
relevance to the treatment of patients with bipolar disorder,
risperidone does not appear to interact with lithium or
valproate. Table 1 summarizes selected potential important
drug interactions with risperidone.
Clinical trials in bipolar mania
A number of double-blind, randomized, controlled trials
(RCTs) and open-label trials of risperidone as monotherapy
and in combination with mood stabilizers have been
conducted with patients with bipolar disorders (Segal et al
1998; Guille et al 2000; Licht et al 2001; Stahl and Shelton
2001; Vieta et al 2001, 2002, 2004; Sachs 2002; Hirschfeld
et al 2003; Yatham et al 2003; Bowden et al 2004; Hirschfield
et al 2004; Ghaemi et al 2004; McIntyre et al 2004; Petrie
2004; Shelton and Stahl 2004; Gopal et al 2005; Khanna et
al 2005; Smulevich et al 2005). These are summarized below
and in Table 2.
Acute mania monotherapy trials
Double-blind trials
One of the earlier trials of risperidone compared with both
lithium and haloperidol was conducted by Segal et al (1998).
This was a small, double-blind, randomized trial where 45
patients were randomized to either risperidone (n = 15), or
lithium (n = 15), or haloperidol (n = 15) for 28 days. The
dosage regimen included risperidone 6 mg/day, haloperidol
10 mg/day, and lithium 400 mg twice daily, with lithium
levels ranging between 0.6 and 1.2 mmol/L. The Young
Mania Rating Scale (YMRS) was the primary outcome
measure for efficacy and Brief Psychiatric Rating Scale
(BPRS), Clinical Global Impression (CGI), and Global
Assessment of Function (GAF) were the secondary
measures. Safety measures included assessment of
extrapyramidal symptoms (EPS) by the Simpson Angus
Scale (SAS).
Table 1 Psychiatric drug interactions with risperidone:
selected agents affecting risperidone levels
Decrease Increase
risperidone levels risperidone levels
carbamazepine chlorpromazine
clomipramine
clozapine
desipramine
duloxetine
fluoxetine
haloperidol
imipramine
paroxetine
pergolide
ropinirole
sertraline
trazodone
verapamilNeuropsychiatric Disease and Treatment 2006:2(2) 130
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Comparable improvement was noted in this trial in all 3
groups on the total score for all rating scales at endpoint
(BPRS: lithium 9.1; haloperidol 4.9; risperidone 6.5;
F = 1.01; df = 2; p = 0.37; YMRS: lithium 15.7; haloperidol
10.2; risperidone 12.4; F=1.07; df = 2; p = 0.35 [analysis of
variance]). Similar improvements were noted in the GAF
and CGI (Segal et al 1998).
A pivotal double-blind trial on bipolar mania was
conducted by Hirschfeld et al (2004). This 3-week,
multicenter, double-blind, placebo-controlled, parallel group
study assessed the efficacy and safety of risperidone in acute
bipolar mania. Inclusion criteria included patients aged 18
or older with a baseline YMRS score of 20 or over and
Montgomery Asberg Depression Rating Scale (MADRS)
score of 20 or less. Study subjects were randomized to either
1–6 mg/day flexible dose of risperidone (n = 134) or placebo
(n = 125). Change in mean total YMRS scores from baseline
to endpoint was the primary efficacy measure and changes
in scores on the CGI (severity), MADRS, GAS, and Positive
and Negative Syndrome Scale (PANSS) were the secondary
measures. The mean modal dose of risperidone was
4.1 ± 0.1 mg/day and the maximum dose allowed was 6 mg/
day. Within the risperidone group, 81% used concomitant
lorazepam compared with 82% of the placebo group, and
22% used antiparkinson medications compared with 11%
of the placebo group. Insufficient response was noted as
the most commonly reported reason for discontinuation from
the study, occurring in 36% of the placebo group compared
with 14% of the risperidone group (χ
2 = 16.26; df = 1;
p < 0.001. There were 8 withdrawals due to adverse events
in the risperidone group and 6 withdrawals due to adverse
events in the placebo group. In this study, the risperidone
group showed statistically significant improvement in the
YMRS scores compared with placebo group at endpoint
(mean change = –10.6, sd = 9.5 vs –4.8, sd = 9.5), with
between-group differences seen as early as 3 days after the
start of treatment (change with risperidone: mean = –6.8,
sd = 5.8; change with placebo: mean = –4.0, sd = 5.8) and
continuing through all time points. The drug–placebo
difference at endpoint was 5.8 in this trial, and Cohen’s effect
size computed from change in baseline YMRS at endpoint
was 0.61. Statistically significant differences were also noted
in the YMRS scores in the risperidone group vs placebo,
when further broken down by patients with psychotic
features (–7.9, sd = 9.5 risperidone vs –2.5, sd = 9.5 placebo;
p = 0.02) and without psychotic features (–11.9, sd = 9.5
risperidone vs –6.0, sd = 9.5 placebo; p = 0.001). Sig-
nificantly greater improvements were also noted in the
secondary measures including CGI severity ratings, scores
on MADRS, PANSS, and Global Assessment Scale (GAS)
in the risperidone group compared with placebo group.
Remission rate (YMRS = ±12 at endpoint) in this trial
for the risperidone group was 38% compared with 20% for
the placebo group. A post-hoc analysis using remission
criteria of YMRS = ≤ 8 showed a rate of 20% for the
risperidone group and 9% for the placebo group.
Khanna et al (2005) conducted a 3-week, randomized,
double-blind, placebo-controlled trial of risperidone in 290
patients (age 18–65 years) with bipolar I disorder with
current manic or mixed episode. The inclusion criteria
Table 2 Double-blind trials of risperidone in bipolar disorder
Number of
Authors Study phase subjects Duration Efficacy results
Segal et al (1998) mania: monotherapy 45 28 days risperidone = haloperidol = lithium
Sachs et al (2002) mania: mixed combination 156 3 weeks risperidone, haloperidol > placebo
with mood stabilizer
Yatham et al (2003) mania: mixed combination 151 3 weeks risperidone = placebo excluding
with mood stabilizer carbamazepine group
risperidone + mood stabilizer > mood
stabilizer alone
Hirschfeld et al (2004) mania: monotherapy 259 3 weeks risperidone > placebo
Petrie et al (2004) mania: mixed combination 37 8 weeks risperidone = olanzapine
with mood stabilizer
Khanna et al (2005) mania: mixed monotherapy 290 3 weeks risperidone > placebo
Smulevich et al (2005) mania: mixed monotherapy 438 3 weeksa risperidone > placebo
Adapted from Sajatovic M, Madhusoodanan S, Fuller MA, et al. 2005. Risperidone for bipolar disorders. Expert Rev Neurother, 5:177–87. Copyright © 2005, with
permission from Future Drugs Ltd.
a 3-week placebo controlled followed by 9-week double-blind risperidone vs haloperidol.Neuropsychiatric Disease and Treatment 2006:2(2) 131
Risperidone for bipolar mania
included a baseline YMRS score of ≥ 20. The primary
efficacy measure was a change in the mean YMRS total
scores from baseline to endpoint. The secondary measures
included scores on the CGI, PANSS, MADRS, and GAS.
Among the risperidone-treated patients, 89% completed the
trial and 71% of the placebo-treated patients completed the
trial. Insufficient response (5% risperidone and 15%
placebo) was the most common reason for discontinuation.
The dropout rate due to adverse effects for the risperidone
group was 3% and for the placebo group was 2%. Study
subjects received flexible doses of risperidone (1–6 mg/day)
or placebo. The mean modal dose of risperidone was
5.6 mg/day. The risperidone group included 146 subjects
and the placebo group 144. Their mean baseline YMRS score
was 37.2 (se = 0.5). Risperidone showed significantly greater
improvement compared with placebo at weeks 1 and 2 and
at endpoint (total YMRS; p < 0.01). EPS were the most
frequently reported adverse events in the risperidone group.
This study concluded that in patients with severe manic
symptoms, risperidone significantly improved YMRS scores
as early as week 1 with substantial changes at endpoint and
treatment was well tolerated.
A separate analysis of the above study group was
conducted by Gopal et al (2005) to assess the rates of
symptomatic remission in patients with bipolar mania
receiving risperidone or placebo. Remission was defined as
achieving and maintaining a YMRS score ≤ 8 for the
remainder of the trial (usually in bipolar trials a responder
is defined as having a ≥ 50% decrease in YMRS scores from
baseline to endpoint). Results of this study showed that 42%
of patients in the risperidone group and 13% in the placebo
group achieved remission. The odds of remission for patients
receiving risperidone were 5.6 (95% confidence interval
[CI] = 3.0–10.4; χ2 =2 9.9, p < 0.0001), after adjusting for
psychosis, baseline YMRS score, sex, number of mood
cycles in the previous year, and treatment. The adjusted
hazard of remission for the risperidone patients was 4.0 (95%
CI = 2.3–6.8; χ
2 = 25.9, p < 0.0001). It was concluded that a
significant proportion of acutely manic patients receiving
risperidone monotherapy achieved symptomatic remission
within 3 weeks.
An international, multicenter, randomized, double-blind
trial was conducted by Smulevich et al (2005), in which
patients with acute bipolar type I mania received 1–6 mg/day
risperidone, 2–12 mg/day haloperidol, or placebo for 3
weeks followed by double-blind risperidone or haloperidol
for 9 weeks. Placebo-treated patients were crossed over to
active treatment. Primary outcome measure was the YMRS
score at baseline and weekly for the first 4 weeks, then every
other week for the duration of the study. The secondary
measures included the CGI, MADRS, BPRS, and GAS.
Safety measures included assessment of EPS using the
Extrapyramidal Symptom Rating Scale (ESRS). The total
number of study subjects was 438 with 154 randomized to
risperidone, 144 to haloperidol, and 140 to placebo. The
initial 3 weeks of double-blind phase of treatment was
completed by 137 (89%) of the risperidone group, 130
(90%) of the haloperidol group, and 119 (85%) of the
placebo group. The total 12-week, double-blind treatment
was completed by 86% (77/90) of patients treated with
risperidone and 88% (56/64) of those treated with
haloperidol. The mean ± sd modal dose of risperidone was
4.2 ± 1.7 and haloperidol 8.0 ± 3.6 during the initial 3-week
phase, and 4.1 ± 1.8 and 7.4 ± 3.7 mg/day during the 12-
week period. Significantly greater reduction from baseline
in YMRS scores were seen in risperidone-treated patients
compared with the placebo group. Differences between
risperidone and haloperidol on the YMRS scores were not
significant. At the end of 3 weeks of treatment, more patients
were treatment responders (≥ 50% reduction in YMRS
score) among the risperidone group (48%) or haloperidol
group (47%) than placebo (33%). The difference between
risperidone and placebo was significant (p < 0.01)
During the 9-week continuation phase, further significant
reductions from baseline in YMRS total scores were seen
in both double-blind continuation treatment groups. Mean
changes from baseline on the YMRS scores for patients who
completed the 12 weeks of double-blind treatment were
–28.7 for the risperidone group (n = 76) and –7.3 for the
haloperidol group (n = 55). An additional 83% of the
risperidone group and 89% of the haloperidol group, who
did not reach a reduction of over 50% in the YMRS total
score at 3 weeks, but continued on double-blind treatment,
were responders at 12 weeks. Greater improvements in
CGI-Severity scores were seen in both active treatment
groups compared with placebo, as early as week 1 and
continuing throughout to weeks 3 and 12. The endpoint
MADRS scores at 12 weeks in the risperidone and
haloperidol groups were similar (4.0 for risperidone and
4.4 for haloperidol). BPRS scores also showed reductions
in both active treatment groups at 12 weeks.
The adverse events reported in this study were mild to
moderate in severity. At week 3, mean changes from baseline
in ESRS total scores were significantly different in the
haloperidol group (p < 0.011), but not in the risperidone
group (p < 0.051). At week 12, mean increases in ESRS totalNeuropsychiatric Disease and Treatment 2006:2(2) 132
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scores were significantly greater with haloperidol than with
risperidone (p < 0.001). Mean increase in weight (± sd) at
12 weeks study endpoint was 1.4 ± 4.6 for the risperidone
group, and 0.8 ± 3.5 in the haloperidol group. During the
3-week initial phase there were 4 withdrawals due to adverse
effects in the risperidone group, 3 in the haloperidol group,
and 5 in the placebo group. During weeks 4–12 in this trial,
there were 6 withdrawals due to adverse effects in the
risperidone group and 5 in the haloperidol group. In
summary, randomized, controlled trials demonstrate that
risperidone is efficacious and relatively well tolerated in
the treatment of bipolar mania (Table 1). A limitation of the
large trials by Hirschfeld et al (2004) and by Khanna et al
(2005) is the short (3-week) duration. This somewhat limits
extrapolation of results interpretation to outcomes,
particularly longer-term tolerability issues that could be
expected in clinical practice. However, the large trial by
Smulevich et al (2005) was followed by a 9-week, double-
blind risperidone vs haloperidol phase, and these data are
perhaps of greatest interest to practitioners caring for patients
with bipolar disorder over the long term.
Open-label trials
Hirschfeld et al (2003) conducted a 9-week, open-label
extension of the 3-week, placebo-controlled, monotherapy
trial in bipolar mania patients discussed earlier in this
section. In this extension phase, risperidone was initiated at
3 mg/day and dosed as needed thereafter. Primary efficacy
measure was the YMRS. Safety measures included the ESRS
for assessment of the EPS. A total of 60% completed the
study. The mean modal dose of risperidone was 3.5 mg/day.
Within-group improvements from baseline of the open-
label study to the endpoint were statistically significant in
both groups who had received placebo and those who had
received risperidone in the double-blind phase of the study.
ESRS median scores were unchanged at zero from baseline
to endpoint in both groups. There was no significant change
in mean body weight from baseline (87.2) to endpoint (87.4)
in the open-label extension phase.
Vieta et al (2001) conducted an open-label, multi-center,
6-month study of risperidone monotherapy in 96 patients
with acute bipolar mania. The efficacy measures included
YMRS, PANSS, and CGI. Highly significant improvements
(p < 0.0001) were noted on all efficacy measures over the
study period. EPS increased significantly by week 4
(p < 0.015) and decreased by study endpoint (p < 0.027). The
mean depression ratings as assessed by the Hamilton
Depression Rating Scale (HAM-D) improved over the 6-
month period (p < 0.00001), while exacerbation of mania
occurred in 4 patients (4.2%). The mean dose of risperidone
in this study was 4.2 mg/day. Weight increase was noted in
13 patients (2.6%). Three patients (0.6%) withdrew from
the study secondary to weight increase.
Combination therapy trials
Double-blind trials
One of the earlier trials was conducted by Sachs et al (2002)
to evaluate the efficacy and safety of risperidone as an
adjunctive therapy to mood stabilizers in bipolar patients
experiencing a manic or mixed episode. The YMRS was
the primary efficacy measure and the BPRS and CGI the
secondary measures. The inclusion criteria included patients’
age (18–65 years) and YMRS score of ≥ 20. Out of the 156
patients, 51 were randomized to placebo, 52 to flexible dose
of risperidone (1–6 mg/day), and 53 to flexible dose of
haloperidol (2–12 mg/day) in addition to mood stabilizers
(lithium or divalproex) for up to 3 weeks after a washout
period of 3 days.
Significant improvements in the YMRS and CGI scores
were noted in both the active treatment groups: risperidone
(–14.3) and haloperidol (–13.4) compared with placebo
(–8.2). Patients with or without psychotic features in both
the risperidone and haloperidol groups showed significant
improvement.
Treatment discontinuation rate in this study for placebo
plus mood stabilizer group was 49%, risperidone plus mood
stabilizer group 28%, and the haloperidol plus mood
stabilizer group 53%. Mean modal dose of risperidone was
3.8 mg/day and of haloperidol 6.2 mg/day; 8% of the placebo
group, 17% of the risperidone group, and 38% of the
haloperidol group of patients received antiparkinson
medications. The between-group difference in the use of
antiparkinson medications was significant for the
haloperidol group compared with the placebo group
(Cochran-Mantel-Haenszel χ
2 = 12.96, df = 1, p = 0.001).
A larger, double-blind, randomized, placebo-controlled
3-week study was conducted by Yatham et al (2003) to assess
the efficacy and safety of risperidone as adjunct therapy to
mood stabilizers (lithium, divalproex, or carbamazepine)
in bipolar I disorder, manic or mixed episode. Inclusion
criteria included hospitalized patients aged 18–65 years with
a baseline YMRS score of ≥ 20 receiving a mood stabilizer.
Out of the 151 patients who were randomized and started
on study medication, 75 received risperidone flexible dosesNeuropsychiatric Disease and Treatment 2006:2(2) 133
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(1–6 mg/day) and 76 placebo. The primary efficacy measure
was the change from baseline in the YMRS score. Other
measures included YMRS, CGI, BPRS, and a 21-item
HAM-D. Assessments were done at baseline, weekly
intervals, and endpoint.
Statistically significant improvement was not seen in the
risperidone group compared with placebo, even though the
YMRS scores improved in the risperidone group. However,
a post-hoc analysis excluding the carbamazepine subgroup
found that YMRS changes were significantly greater in the
risperidone plus mood stabilizer group at endpoint. In the
subgroup that excluded recipients of concomitant
carbamazepine, change from baseline YMRS for
risperidone-treated patients was –15.2 compared with –9.8
in placebo-treated patients (p < 0.05). Endpoint plasma
concentrations of risperidone and/or risperidone plus
9-hydroxyrisperidone (normalized for the median 4 mg
risperidone dosage) in the subgroup patients were
approximately 40% lower than in other risperidone-treated
patients. Treatment discontinuation rates and adverse event
incidence were similar in both groups in this trial.The mean
modal dose of risperidone was 4 mg/day. The most
frequently reported adverse events included EPS (21.3% in
risperidone group vs 8% in placebo group), headache (9%
in each group), insomnia (4% vs 8%), and nausea (5% vs
3%). The mean weight change from baseline to endpoint
was +1.7 kg for the risperidone group and +0.5 kg for the
placebo group (p = 0.012). No clinically significant changes
in laboratory values were observed in either group. No
specific information regarding blood sugar–lipid changes
are reported is the trial.
A small 8-week, double-blind, adjunctive trial of
risperidone was conducted by Petrie (2004) comparing
risperidone (n = 16) and olanzapine (n = 21) in 37 patients
with bipolar mania, who were on mood stabilizers (lithium
or divalproex). The primary outcome measure was the
YMRS and secondary measures included the BPRS, CGI,
and HAM-D. EPS was assessed by the Abnormal
Involuntary Movement Scale (AIMS), the Barnes Akathisia
Scale (BAS), and the SAS. Ten out of 16 risperidone patients
and 14 out of 21 olanzapine patients completed this 8-week
trial. Similar improvements were noted on all efficacy
measures in both groups at study endpoint. EPS ratings were
minimal in both groups. Mean weight gain was significantly
greater (p < 0.05) in the olanzapine group (3.6 kg) compared
with the risperidone group (0.87 kg).
In summary, randomized, controlled combination trials
demonstrate that risperidone augmentation is efficacious and
relatively well tolerated for treatment of patients with bipolar
mania. Trials by Sachs et al (2002) and by Yatham et al
(2003) were large studies involving more than 250 patients.
As with monotherapy trials, the 3-week duration of the
largest trials somewhat limit interpretation of tolerability
findings as they relate to clinical practice settings. However,
as most bipolar patients in a clinical setting are likely to
receive treatment with more than one medication, tolerability
and dosing results from large, combination-therapy trials
may be particularly relevant to a clinical practice setting.
Open-label trials
A large open-label, multi-center, 6-week study was
conducted by Vieta et al (2002) to assess the efficacy and
safety of risperidone as adjunctive therapy to mood
stabilizers in 174 patients with bipolar disorder, experiencing
a manic (YMRS score > 20), hypomanic (YMRS > 7), or
mixed episode (YMRS > 7). The efficacy measures included
the YMRS, PANSS, HAM-D, and CGI. The safety measures
included the Udvalg for Kliniske Undersogelser (UKU)
scale for EPS. Out of the 159 patients who completed the
study, 10% received risperidone monotherapy, 42%
risperidone in combination with lithium, 16% risperidone
in combination with lithium and another mood stabilizer,
23% risperidone in combination with carbamazepine, and
12% risperidone in combination with valproate. Four
patients discontinued the study due to lack of response, 4
due to side-effects, 2 due to withdrawal of consent, and 3
were lost to follow-up.
Significant improvements were noted in the YMRS and
HAM-D scores over the 6-week study period (p < 0.0001)
and in PANSS over first the 4 weeks of study (p < 0.0001).
The CGI ratings improved in 22.5% of patients. No
significant difference was noted in the EPS ratings as
measured by UKU at baseline and week 4. The adverse
events reported include EPS, drowsiness, weight gain, dry
mouth, impotence, dizziness, weight loss, hypotension, and
impaired concentration and amenorrhea.
In a 12-week study of risperidone added on to mood
stabilizers in 108 patients with bipolar mania, Yatham et al
(2003) found significant decreases in YMRS scores from
baseline to week 1 (–10.8, p < 0.0001), continuing through
to week 3 (–17.1, p < 0.0001) and week 12 (–22.6,
p < 0.0001). 32% of patients responded to risperidone
treatment (defined as ≥ 50% reduction in YMRS) at week
1, 68% at week 3, and 90% at week 12. Significant decreases
in HAM-D scores from baseline to endpoint were also noted.
No significant changes in EPS were noted during the studyNeuropsychiatric Disease and Treatment 2006:2(2) 134
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duration. The mean daily dose of risperidone was 2 mg/day.
It is of interest that the dose of risperidone in this study was
relatively low compared with that in some other trials,
possibly because risperidone therapy was used as an add-
on to mood stabilizers in this instance.
Bowden et al (2004) conducted a 10-week, open-label.
continuation phase from a 3-week combination treatment
trial (lithium or valproate plus placebo, risperidone or
haloperidol). Out of 156 patients enrolled in the 3-week
study, 85 entered the open-label extension phase and 48
completed the 10-week endpoint. Significant improvements
were noted compared with placebo (p < 0.001) in the YMRS
scores in risperidone-treated patients at the conclusion of
the double-blind phase and the 10-week open-label phase.
Symptom remission (YMRS ≤ 12) was seen in 38 patients
at the end of the 10-week study.
The BPRS, CGI, and HAM-D scores also showed
significant improvement (p < 0.05) during both phases of
the study. Treatment was well tolerated and modest weight
gain was noted.
Longer-term bipolar trials
A 6-month, open-label, multi-center study by Vieta et al
(2001) compared the efficacy and safety of risperidone
in bipolar manic (YMRS ≥ 20), hypomanic (YMRS ≥ 7),
depressed (HAM-D > 7), or mixed (YMRS ≥ 7) episodes
or schizoaffective disorder. The reduction in YMRS
scores from baseline to endpoint was the primary efficacy
measure. Secondary measures included the HAM-D,
PANSS, and CGI. EPS was assessed by the UKU scale.
The mean dose of risperidone at baseline was 4 mg/day
and at 6 months 3.9 mg/day. A total of 430 patients
completed the study. Patients who received addition of
risperidone showed highly significant improvements
(p < 0.0001) on the YMRS and HAM-D at both 6 weeks
and 6 months, and on the CGI and PANSS at both 4 weeks
and 6 months. The most frequently reported adverse
events were motor side-effects and weight gain.
Significant improvement (p < 0.0001) was noted in the
mean UKU scores from baseline to endpoint. No new
cases of tardive dyskinesia were observed during the
study period.
While open-label studies, including longer trials such
as the study by Vieta et al (2001), do not provide
comparative data in terms of efficacy and tolerability,
tolerability findings and dosing in these longer-term,
outpatient trials may be particularly relevant to a clinical
practice setting.
Geriatric and child populations
Elderly
Psychopharmacological treatment of the elderly patient with
bipolar disorder is complicated by the various pharmaco-
kinetic and pharmacodynamic vulnerabilities of the elderly,
concurrent medications, and concomitant medical
conditions. Renal clearance of risperidone and its active
metabolite 9-hydroxy risperidone are decreased in the
elderly and the elimination half-lives are prolonged. The
expert consensus guideline series on the treatment of Bipolar
Disorder (Keck et al 2004) recommend risperidone as the
preferred (first-line) atypical antipsychotic agent along with
quetiapine as a first-line agent for the treatment of bipolar
disorder in the elderly. There are no controlled studies of
risperidone for bipolar disorder in the elderly. Anecdotal
case reports and retrospective reviews (Sajatovic 1996)
indicate clinical improvement and moderate tolerability with
risperidone in bipolar patients, but data interpretation is
limited by the small sample size of these reports. Controlled
studies with larger sample size are required to further
investigate the use of risperidone in the elderly bipolar
patients.
Children
None of the atypical antipsychotics are approved by the FDA
for treatment of bipolar disorder in children or adolescents.
However, recent guidelines have been developed that address
the diagnosis, comorbidity, acute treatment, and
maintenance treatment of bipolar disorder in children and
adolescents (Kowatch et al 2005). The guidelines by
Kowatch and colleagues (2005) note that monotherapy with
traditional mood stabilizers such as lithium, divalproex, and
carbamazepine as well as the atypical antipsychotic
compounds olanzapine, risperidone, and quetiapine are
determined to be first-line treatments for bipolar disorder I
manic or mixed presentation in children–adolescent
populations. The expert consensus guidelines (Keck et al
2004) do not identify any specific atypical antipsychotic as
first-line treatment for bipolar disorder in adolescents.
Risperidone is recommended as high second-line treatment
along with other atypical antipsychotics except clozapine.
Biederman (2003) conducted an open-label, 8-week
study of risperidone in 30 outpatient children and
adolescents aged 6–17 years with bipolar disorder. The
inclusion criteria included a YMRS score of ≥ 15. The dose
range for children up to 12 years of age was 0.25–2 mg/day;
for older adolescents, the dose range was 0.5–4 mg/day. TheNeuropsychiatric Disease and Treatment 2006:2(2) 135
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YMRS scores improved significantly from baseline to
endpoint.
Frazier et al (1999) conducted a retrospective study of
risperidone in 28 children and young adolescents with
bipolar disorder. The mean dose of risperidone was 1.7 mg
and mean duration of treatment 6.1 months. Response was
assessed by CGI-Improvement Scale and was achieved by
82% of patients. Weight gain, somnolence, and sialorrea
were the common adverse events.
As in the case of the elderly, data are limited on the use
of risperidone in bipolar disorder in children and
adolescents. Controlled, well-designed studies are needed
to further investigate the role of risperidone in bipolar
disorder in children.
Safety and tolerability issues
Common adverse events
Based upon results of controlled studies of risperidone
therapy in bipolar mania, risperidone was generally well
tolerated both when used as monotherapy and in
combination therapy with mood-stabilizing compounds.
Percentages of patients who discontinued controlled-study
participation due to side-effects was not greater compared
with placebo (Fenton and Scott 2005; Sajatovic et al 2005).
In the RCT reported by Hirschfeld et al (2004) adverse
events occurring in > 10% of bipolar patients included
somnolence, headache, hyperkinesia, dyspepsia, and nausea.
Somnolence was the most common adverse event reported
among risperidone-treated patients (28%). The total scores
for ESRS were significantly greater in the risperidone than
the placebo group. However, the subscales for Parkinsonism,
dystonia, and dyskinesia did not show any significant
differences at endpoint between the groups. Mean weight
gain vs placebo was generally significant, ranging from 0.3
to 2.4 kg, in most randomized, controlled trials (Sachs et al
2002; Hirschfeld et al 2004; Smulevich et al 2005). However,
in the trial by Khanna et al (2005), mean body weight
changes from baseline to endpoint were +0.1 kg in both
groups.
Manic reaction did not occur with increased frequency
in risperidone-treated compared with placebo-treated
patients (Sachs et al 2002; Hirschfeld et al 2004; Smulevich
et al 2005), and Hirschfeld et al (2004) reported no evidence
of treatment-emergent depression associated with
risperidone therapy. Rare adverse effects reported in open-
label trials of risperidone therapy (adjunct or combination)
included seizures in two individuals (Bahk et al 2004), and
single-case reports of neuroleptic malignant syndrome,
dysuria, dyskinesia, and confusion (Bahk et al 2004;
Bowden et al 2004; Vieta et al 2004). An open-label trial by
Vieta et al (2004) noted study withdrawal in four individuals
treated with risperidone for adverse effects that included
akathisia, impotence, drowsiness, and weight gain. There
were no cases of clinically relevant QT interval prolongation
noted with risperidone therapy (Sachs et al 2002; Khanna
et al 2003; Yatham et al 2003; Hirschfeld et al 2004;
Smulevich et al 2005). Finally, serious cerbrovascular events,
and increased rate of fatalities have occurred in elderly
patients with dementia and behavioral disturbances who
received risperidone therapy compared with placebo,
although this has not been documented in individuals treated
for bipolar mania (FDA 2005).
Extrapyramidal symptoms
Risperidone therapy has been associated with increased rates
of extrapyramidal side-effects compared with placebo based
upon controlled studies. Rates of extrapyramidal symptoms
seen with risperidone therapy are lower than rates seen with
haloperidol. Although extrapyramidal disorder was the most
common adverse event in the monotherapy study by
Smulevich et al (2005), the rate was relatively low; 17% for
risperidone compared with a rate of 40% in the haloperidol
group at the 3-week point in the study. In a
6-month, open-label study (Vieta et al 2004), extrapyramidal
symptoms associated with risperidone were noted to be
dose-dependent. Symptoms were greater when risperidone
dosage was 4.5 mg/day, but decreased significantly
(p = 0.027) when dosage was decreased to 3 mg/day by the
end of the trial (Vieta et al 2004). Given the dose relationship
between extrapyramidal symptoms and risperidone,
determination of lowest effective dosing is critical in
achieving medication level that will balance the need for
antipsychotic efficacy and tolerability.
Metabolic concerns
As requested by the FDA, all manufacturers of atypical
antipsychotics have revised the labeling for their atypical
antipsychotic to highlight the potential for diabetes (Janssen
2003b). This information has been summarized by a
Consensus Panel (ADA 2004). Severe hyperglycemia,
including ketosis, has been documented in patients receiving
this class of medications. Clozapine and olanzapine have
been most clearly associated with these effects, while
risperidone and quetiapine have produced discrepant results.
Aripiprazole and ziprasidone are associated with little or
no diabetes, but have not been used as extensively as theNeuropsychiatric Disease and Treatment 2006:2(2) 136
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other agents implicated and therefore the exact risk is
unknown.
In short-term risperidone therapy trials modest weight
gain has been noted. In a 3-week, risperidone monotherapy
trial (Hirschfeld et al 2004), mean body weight changes
were 1.6 kg (sd 2.2) in risperidone-treated patients and
–0.25 kg (sd 2.4) in placebo-treated patients (t = 6.47,
df = 225, p < 0.001). In a 3-week, combination therapy, acute
mania treatment trial (Sachs et al 2002), weight gain in
risperidone plus mood-stabilizer-treated patients was
significantly greater than in patients treated with mood
stabilizer plus placebo (t = 2.95,
 df = 105, p < 0.004).
However, risperidone may be associated with clinically
significant weight gain in some patients, particularly when
prescribed over a longer time period and with concomitant
traditional mood-stabilizing medication. Yatham et al (2003)
reported clinically significant weight gain (more than 7%)
in 21% of individuals receiving adjunctive mood stabilizers
over 12 weeks, while Vieta et al (2004) reported significant
weight gain in 9.4% of individuals on risperidone
monotherapy over a 6-month time period.
Risperidone may be associated with impaired glucose
tolerance or diabetes mellitus (Newcomer et al 2002; ADA
2004). A prospective, randomized, double-blind, 14-week
trial (Lindenmayer et al 2003) assessed the effects of
clozapine, olanzapine, risperidone,
 and haloperidol on
glucose and cholesterol levels in hospitalized
 patients with
schizophrenia or schizoaffective disorder (n = 108). The
mean glucose levels were obtained at the end of an 8-week,
fixed-dose period and a 6-week, variable-dose period.
Increases in glucose levels were highest for olanzapine,
followed by
 clozapine and risperidone. In the study by
Lindenmayer and colleagues (2003), 14 out of 101 patients
developed abnormal glucose levels (> 125 mg/dL) during
the trial (6 with clozapine, 4 with olanzapine, 3 with
risperidone, and 1 with haloperidol).
Patients treated with an atypical antipsychotic
medication and in particular those with established diabetes
(or with risk factors such as a family history or obesity)
should be monitored closely for changes in weight, lipids,
and glucose control. Monitoring of these parameters at the
beginning of therapy and periodic monitoring during therapy
are recommended (ADA 2004).
As with other drugs that antagonize dopamine D2
receptors, risperidone elevates prolactin levels. In a 3-week,
double-blind, placebo-controlled trial (Hirschfeld et al 2004)
for risperidone-treated patients, the mean plasma prolactin
levels increased from 13.7 ng/mL (sd = 9.8) to 43.5 ng/mL
(sd = 23.0) in men, and from 19.4 ng/mL (sd = 26.6) to
96.1 ng/mL (sd = 51.4) in women. In this 3-week trial, there
was no correlation with adverse events for hyper-
prolactinemia. However, in a 12-week trial, prolactin-related
adverse effects including decreased libido and abnormal
sexual function, nonpuerperal lactation, breast pain, and
dysmenorrhea occurred in 4% of risperidone-treated and
1% of haloperidol-treated patients (Smulevich 2005).
Prolactin-related adverse effects may occur in both men and
women, and should be assessed in patients on risperidone.
As is the case with extrapyramidal symptoms, prolactin
effects with risperidone may be minimized by establishing
lowest effective dosing.
In summary, risperidone appears relatively well tolerated
in bipolar manic patients. In clinical settings weight gain
and metabolic concerns may be less with risperidone than
with some atypical antipsychotic compounds such as
olanzapine and clozapine, while sedation and orthostasis
may be less problematic with risperidone than with
compounds such as quetiapine (Fuller and Sajatovic 2005).
In contrast, extrapyramidal symptoms may be a greater
concern with risperidone compared with some atypicals such
as olanzapine and quetiapine (Fuller and Sajatovic 2005).
Dosage and administration
Recommended dosing of risperidone in bipolar mania is
2–3 mg once daily. In more severely ill hospitalized patients
such as those included in pivotal trials higher doses may
sometimes be required. If needed, this may be adjusted by
1 mg/day in intervals of approximately 1 day. Suggested
dosing range is 1–6 mg/day in healthy individuals (Fuller
and Sajatovic 2005). In the elderly, a starting dose of
0.25–1 mg in 1–2 divided doses is recommended, with slow
titration if needed. If once-daily dosing in elderly or
debilitated individuals is considered, a twice-daily regimen
should be used to titrate to target dose, and this dose
maintained for 2–3 days prior to switching to once-daily
dosing. Children and adolescents with bipolar mania may
be treated with an initial dose of 0.5 mg, and gradually
titrated to 0.5–3.0 mg/day (Fuller and Sajatovic 2005).
Dosing adjustment for renal impairment is suggested,
as clearance of the active moiety of risperidone is decreased
by 60% in individuals with moderate to severe renal disease
(Fuller and Sajatovic 2005). Dosing may also need
adjustment in those with hepatic dysfunction, as it has been
noted that mean fraction of risperidone in plasma wasNeuropsychiatric Disease and Treatment 2006:2(2) 137
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increased by 35% in individuals with hepatic impairment
compared with healthy subjects (Fuller and Sajatovic 2005).
Conclusions
Risperidone is an atypical antipsychotic medication with
demonstrated efficacy and relatively good tolerability in the
treatment of patients with acute bipolar mania. Current
practice guidelines for bipolar disorder support the use of
atypical antipsychotic medications as monotherapy or as a
component of polytherapy–cotherapy. While findings from
randomized, controlled, monotherapy trials are clearly
important, in clinical settings polytherapy for bipolar
disorder is much more common than monotherapy.
In clinical practice settings, risperidone is widely utilized
to treat acute mania, often in conjunction with traditional
mood stabilizers such as lithium or valproate, and is often
subsequently utilized as part of a longer-term medication
treatment regimen. As with any drug treatment, medication
selection ideally involves an analysis of demographic
factors, including family and personal history of response
to a particular agent as well as attention to potential side-
effects and drug interactions. Unfortunately, as demonstrated
in our review, most controlled studies of bipolar mania are
of relatively limited duration and with research populations
that do not necessarily represent the majority of clinical
bipolar populations. Large-scale, multi-center studies that
examine the longitudinal course of bipolar disorder and the
effectiveness of current treatments in diverse populations
and using all or most available treatments such as the
Systematic Treatment Enhancement Program for Bipolar
Disorder (STEP-BD) study will be an important future
source of information in helping clinicians to determine best
treatments for individual patients with bipolar disorder
(Kogan et al 2004; Sachs et al 2004).
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